No Data
YaHong Pharmaceutical (688176): Revenue in the first three quarters exceeded expectations, APL-1706 approved for market launch.
1-3Q24 revenue higher than our expectationsCompany announced 1-3Q24 performance: revenue 0.139 billion yuan, single third quarter revenue 58.46 million yuan, revenue for the first three quarters higher than our expectations, mainly due to Dpart and Ououbi 4
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Report for the Third Quarter of 2024
Yahong Pharmaceuticals (688176.SH): Net loss of 0.271 billion yuan in the first three quarters.
As of October 29, GeLongHui reported that Yuhong Medicine (688176.SH) achieved total operating income of 0.139 billion yuan in the first three quarters of 2024, an increase of 4537.79% year-on-year; net income attributable to the parent company's shareholders was -0.271 billion yuan; basic earnings per share was -0.48 yuan.
Yahong Pharmaceuticals accumulated revenue of 0.139 billion yuan in the first three quarters of this year, with two commercialized products continuing to ramp up production.
On the evening of October 29, YAHONG PHARMACEUTICAL (688176.SH) disclosed its third quarter report. The company achieved revenue of 58.4582 million yuan in the third quarter, a year-on-year increase of 1903.16%; for the first three quarters, the cumulative revenue was 0.139 billion yuan, a year-on-year increase of 4537.79%. The revenue growth is mainly attributed to the company starting to sell its drug Pipatinib Tablets (brand name: Dipatte) and Nilotinib Maleate Tablets (brand name: Ouyoubi) in the fourth quarter of 2023. Commercial promotion has steadily progressed during this reporting period, leading to an increase in sales volume.
Yahong Pharmaceutical (688176.SH): The clinical trial application for APL-2302 has been approved by the FDA.
Granger October 24th ǀ Asia Rainbow Pharmaceutical (688176.SH) announced that it has received a letter from the Food and Drug Administration (FDA) of the United States agreeing to conduct clinical trials of APL-2302, developed independently by the company, for the treatment of advanced solid tumors. APL-2302 is a ubiquitin-specific protease 1 (USP1) inhibitor developed independently by the company, which exerts anti-tumor effects through a mechanism of "synthetic lethality". Preclinical studies have shown good in vitro and in vivo activity of APL-2302 in tumor suppression as a monotherapy and in combination therapy. APL-2302 has the potential to become.
Express News | Yahong Pharma: APL-2302 clinical trial approved by FDA.
No Data
No Data